Coherus Biosimilar Used ‘Scientific Justification’ To Skip Switch Study, Still Get Interchangeability With Lucentis

 
• By Sue Sutter
  
Generate a summary of this article
Listen to this article
Beta

Information on mechanism of action, pharmacokinetics, immunogenicity and toxicity convinced the US FDA there was no risk in terms of safety or diminished efficacy of switching between Cimerli and the reference product, Genentech’s eye drug Lucentis.

Lucentis Biosimilar Drug review profile
Cimerli was not subject to a 'switching' study prior to earning an interchangeability nod. • Source: Shutterstock

Coherus BioSciences, Inc. and partner Bioeq IP AG provided “sufficient justification” that Cimerli (ranibizumab-eqrn), a biosimilar of Genentech, Inc.’s macular degeneration treatment Lucentis (ranibizumab), will produce the same clinical result in any given patient for each condition of use, the US Food and Drug Administration said in deciding to award an interchangeability designation in the absence of a “switching” study.

This scientific justification took into account information on mechanism of action, pharmacokinetics, immunogenicity and toxicity, the FDA said in a...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Drug Review Profiles

Akebia’s Vafseo: Japanese Postmarketing Data, Narrowed Indication Eased Liver Toxicity Worries

 
• By Sue Sutter

The Pink Sheet Drug Review Profile explores the US FDA’s approval of vadadustat to treat anemia in chronic kidney disease patients on dialysis. A complete response letter cited the risk of drug-induced liver injury, but postmarketing data from Japan reassured reviewers.

Vafseo Chronology: Complete Response Letter, Dispute Resolution And A Second-Cycle Approval

 
• By Sue Sutter

The Pink Sheet’s Drug Review Profile looks at the timeline behind the development and US FDA approval of Akebia’s Vafseo, a treatment for anemia in chronic kidney disease patients on dialysis.

The Next 340B Battle: Discount Duplication With Medicare Negotiated Prices

 
• By Cathy Kelly

Manufacturers likely will have to determine when to provide a 340B discount on a drug assigned a Medicare negotiated price under CMS guidance. PhRMA anticipates the job will not be easy.

More from Product Reviews

data

New EU Filings

 
• By Saba Afreen

<p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

data

EU CHMP Opinions And MAA Updates

 
• By Saba Afreen

<p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

EU Biosimilar Filings, Opinions And Approvals

 
• By Saba Afreen

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>